SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) — Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and […]
CUE-101 Demonstrates Selective Binding and Preferential Activation/Expansion of Antigen-specific T Cells, Inhibition of Tumor Growth as Monotherapy and in Combination […]
– Demonstrates Further Proof-of-Mechanism of Probody™ Platform – – Consistent with CX-072 Clinical Observations at 2018 ASCO and ESMO Presentations- […]